Abstract
“Oxidative Stress” denotes an imbalance between oxidants and antioxidants in favor of the oxidants, leading to a disruption of redox signaling and control and/or molecular damage. It is fascinating to note the development of the general concept of “oxidative stress” from basic chemistry of biomolecules to detailed ramifications in neurodegenerative diseases. This brief introduction to the book, “Oxidative Stress and Alzheimer’s Disease,” intends to delineate this development which extends over more than a quarter-century. One exemplary field of research in neuroscience, namely that of selenium, selenocompounds and selenoproteins, will be presented in some detail.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sies H. Oxidative stress: introductory remarks. In: Sies H, editor. Oxidative stress. London: Academic; 1985. p. 1–8.
Sies H. Biochemistry of oxidative stress. Angew Chem Int Ed Engl. 1986;25:1058–71.
Sies H, Jones D. Oxidative Stress. In: Fink G, editor. Encyclopedia of stress. Amsterdam: Elsevier; 2007. p. 45–8.
Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262:689–95.
Zhu X, Castellani RJ, Moreira PI, Aliev G, Shenk JC, Siedlak SL, Harris PL, Fujioka H, Sayre LM, et al. Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radic Biol Med. 2012;52:699–704.
Behl C, Davis JB, Lesley R, Schubert D. Hydrogen-peroxide mediates amyloid-beta protein toxicity. Cell Jun 17 1994;77:817–827.
Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012;69(7):836–41.
Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci. 2012;33(6):295–303.
Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors. 2012;38:133–8.
Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010 Nov;84:825–89.
Santos RX, Correia SC, Zhu X, Lee HG, Petersen RB, Nunomura A, Smith MA, Perry G, Moreira PI. Nuclear and mitochondrial DNA oxidation in Alzheimer’s disease. Free Radic Res. 2012;46:565–76.
Du H, Guo L, Yan SS. Synaptic mitochondrial pathology in Alzheimer’s disease. Antioxid Redox Signal. 2012 Jun 15;16:1467–75.
Hedskog L, Zhang S, Ankarcrona M. Strategic role for mitochondria in Alzheimer’s disease and cancer. Antioxid Redox Signal. 2012 Jun 15;16:1476–91.
Leuner K, Schutt T, Kurz C, Eckert SH, Schiller C, Occhipinti A, Mai S, Jendrach M, Eckert GP, et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal. 2012;16:1421–33.
Schmitt K, Grimm A, Kazmierczak A, Strosznajder JB, Gotz J, Eckert A. Insights into mitochondrial dysfunction: aging, amyloid-beta, and tau-A deleterious trio. Antioxid Redox Signal. 2012;16:1456–66.
Swerdlow RH. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer’s disease. Antioxid Redox Signal. 2012;16:1434–55.
Atamna H, Mackey J, Dhahbi JM. Mitochondrial pharmacology: electron transport chain bypass as strategies to treat mitochondrial dysfunction. Biofactors. 2012 Mar;38:158–66.
Smith RA, Hartley RC, Cocheme HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012;33(6):341–52.
Packer L, Sies H, Eggersdorfer M, Cadenas E. Micronutrients and brain health. Boca Raton: CRC Press; 2010.
Muller A, Cadenas E, Graf P, Sies H. A novel biologically active seleno-organic compound–I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol. 1984;33:3235–9.
Parnham M, Sies H. Ebselen: prospective therapy for cerebral ischaemia. Expert Opin Investig Drugs. 2000;9:607–19.
Gladilin S, Bidmon HJ, Divanach A, Arteel GE, Witte OW, Zilles K, Sies H. Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia. Arch Biochem Biophys. 2000;380:237–42.
Burk RF, Hill KE. Selenoprotein P-expression, functions, and roles in mammals. Biochim Biophys Acta. 2009 Nov;1790:1441–7.
Arteel GE, Mostert V, Oubrahim H, Briviba K, Abel J, Sies H. Protection by selenoprotein P in human plasma against peroxynitrite-mediated oxidation and nitration. Biol Chem. 1998 Aug;379:1201–5.
Scharpf M, Schweizer U, Arzberger T, Roggendorf W, Schomburg L, Kohrle J. Neuronal and ependymal expression of selenoprotein P in the human brain. J Neural Transm. 2007 Jul;114:877–84.
Steinbrenner H, Alili L, Bilgic E, Sies H, Brenneisen P. Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic Biol Med. 2006 May 1;40:1513–23.
Steinbrenner H, Bilgic E, Alili L, Sies H, Brenneisen P. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic Res. 2006 Sep;40:936–43.
Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta. 2009 Nov;1790:1478–85.
Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, Rajanayagam O, Padidela R, Ceron-Gutierrez L, Doffinger R, et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest. 2010 Dec;120:4220–35.
Schweizer U, Dehina N, Schomburg L. Disorders of selenium metabolism and selenoprotein function. Curr Opin Pediatr. 2011 Aug;23:429–35.
Berr C, Arnaud J, Akbaraly TN. Selenium and cognitive impairment: a brief-review based on results from the EVA study. Biofactors. 2012 Mar;38:139–44.
Pitts MW, Raman AV, Hashimoto AC, Todorovic C, Nichols RA, Berry MJ. Deletion of selenoprotein P results in impaired function of parvalbumin interneurons and alterations in fear learning and sensomotor gating. Neuroscience. 2012;208:58–68.
Raman AV, Pitts MW, Seyedali A, Hashimoto AC, Seale LA, Bellinger FP, Berry MJ. Absence of selenoprotein P but not selenocysteine lyase results in severe neurological dysfunction. Genes Brain Behav. 2012;6:10–183X.
Caito SW, Milatovic D, Hill KE, Aschner M, Burk RF, Valentine WM. Progression of neurodegeneration and morphologic changes in the brains of juvenile mice with selenoprotein P deleted. Brain Res. 2011;1398:1–12. Epub@2011 May 5:1–12.
Murphy MP, Holmgren A, Larsson NG, Halliwell B, Chang CJ, Kalyanaraman B, Rhee SG, Thornalley PJ, Partridge L, et al. Unraveling the biological roles of reactive oxygen species. Cell Metab. 2011;13:361–6.
Steinbrenner H, Sies H. Selenium homeostasis and antioxidant selenoproteins in brain: implications for disorders in the central nervous system. Arch Biochem Biophys. 2013 Mar 13. doi:pii: S0003–9861(13)00081–7. 10.1016/j.abb.2013.02.021.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sies, H. (2013). Oxidative Stress: Impact in Neuroscience Research. In: Praticὸ, D., Mecocci, P. (eds) Studies on Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-598-9_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-598-9_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-597-2
Online ISBN: 978-1-62703-598-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)